Related Experiment Video
Updated: Oct 13, 2026

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
Published on: July 29, 2014
Morphine antinociception is enhanced in mdr1a gene-deficient mice
1Division of Drug Delivery and Disposition, School of Pharmacy, University of North Carolina at Chapel Hill 27599-7360, USA.
Purpose:
Previous studies have suggested that P-glycoprotein (P-gp) modulates opioid antinociception for selected mu-and delta-agonists. This study was undertaken to assess morphine antinociception in mice lacking the mdr1a gene for expression of P-gp in the CNS.
Methods:
Morphine (n = 4-5/group) was administered as a single s.c. dose to mdr1a(-/-) mice (3-5 mg/kg) or wild-type FVB controls (8-10 mg/kg). Tail-flick response to radiant heat, expressed as percent of maximum response (%MPR), was used to determine the antinociceptive effect of morphine. Concentrations in serum, brain tissue, and spinal cord samples obtained immediately after the tail-flick test were determined by HPLC with fluorescence detection. Parallel experiments with R(+)-verapamil, a chemical inhibitor of P-gp, also were performed to further investigate the effect of P-gp on morphine-associated antinociception.
Results:
Morphine-associated antinociception was increased significantly in the mdr1a(-/-) mice. The ED50 for morphine was > 2-fold lower in mdr1a(-/-) (3.8+/-0.2 mg/kg) compared to FVB (8.8+/-0.2 mg/kg) mice. However, the EC50 derived from the brain tissue was similar between the two mouse strains (295 ng/g vs. 371 ng/g). Pretreatment with R(+)-verapamil produced changes similar to those observed in gene-deficient mice. P-gp does not appear to affect morphine distribution between spinal cord and blood, as the spinal cord:serum morphine concentration ratio was similar between gene-deficient and wild-type mice (0.47+/-0.03 vs. 0.56+/-0.04, p>0.05).
Conclusions:
The results of this study are consistent with the hypothesis that P-gp attenuates the antinociceptive action of morphine by limiting the brain:blood partitioning of the opioid.
Insights
P-glycoprotein (P-gp) reduces morphine
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- P-glycoprotein (P-gp) is a key efflux transporter in the central nervous system (CNS).
- Previous research suggests P-gp influences opioid antinociception.
Purpose of the Study:
- To investigate the role of P-gp in morphine antinociception.
- To assess morphine's effects in mice lacking CNS P-gp expression (mdr1a gene knockout).
Main Methods:
- Morphine administered to mdr1a(-/-) and wild-type mice.
- Antinociception measured via tail-flick test.
- Morphine concentrations analyzed in serum, brain, and spinal cord using HPLC.
- Experiments included R(+)-verapamil, a P-gp inhibitor.
Main Results:
- Morphine antinociception was significantly enhanced in mdr1a(-/-) mice (lower ED50).
- Brain morphine concentrations were similar between groups.
- R(+)-verapamil mimicked the effects seen in gene-deficient mice.
- Spinal cord to serum morphine ratio was unaffected by P-gp deficiency.
Conclusions:
- P-gp attenuates morphine's antinociceptive action.
- This attenuation occurs by limiting morphine's distribution into the brain.
- Findings support P-gp as a modulator of central opioid effects.
Related Concept Videos
Analgesia and Pain Management
Opioid Receptors: Overview
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Opioid Analgesics: Morphine and Other Natural Cogeners

